CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Biotoscana Investments SA is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Biotoscana Investments SA
70, Route d'Esch
Luxembourg, 1470  Luxembourg
This company was Merged or Acquired on 11/29/2019.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Biotoscana Investments SA is a Luxembourg-based company engaged in the healthcare industry. The Company develops, manufactures and distributes pharmaceutical products. The Company offers drugs for the treatment of infectious and rare diseases, oncology, onco-hematology, special treatments and immunology, among others. Its product development pipeline is divided into two business models: partnership product development, which is focused on building relationships to license and commercialize products that are new to Latin America, and internal product development, which is focused on studying, designing, formulating and manufacturing branded generic products. Apart from the Luxembourg, the Company operates worldwide in a number of countries, including Peru, Argentina and Ecuador, among others.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202012/31/2019Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Business Names
Business Name
BIO
GBIO33
Laboratorio DOSA

General Information
Number of Employees: 676 (As of 3/31/2020)
Outstanding Shares: 106,132,070 (As of 3/31/2020)
Stock Exchange: SAO


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, December 31, 2023